Vernal Biosciences, a Colchester, VT-based mRNA manufacturer and formulator of LNP-mRNA, closed a $21 million financing.
The round was led by Ampersand Capital Partners and Dynamk Capital, with existing investors Alloy Therapeutics and ATUM participating and new investor Charles River Laboratories, Inc.
The funds from this financing will support the company’s growth including the construction of full GMP capabilities scheduled to become operational in late 2023.
Christian Cobaugh is the CEO and founder of Vernal. He offers a full range of mRNA-related products and services, including sequence design and screening support as well as scaled-down or scale-up manufacturing of high-purity mRNA and LNP mRNA. Platform process development technologies and finally GMP manufacturing for all use cases, from drug discovery to clinical trials across all use scenarios such gene editing, regulation, vaccines and oncology.
Cobaugh will be joined on Vernal’s board by existing board member, Errik Anderson of Alloy Therapeutics, and new board members, David Anderson of Ampersand, and Gustavo Mahler of Dynamk.